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Coagulase-negative Staphylococcus has been identiﬁed as the main nosocomial agent of
neonatal late-onset sepsis. However, based on the pharmacokinetics and erratic distribution
of  vancomycin, recommended empirical dose is not ideal, due to the inappropriate serum
levels that have been measured in neonates. The aim of this study was to evaluate serum
levels  of vancomycin used in newborns and compare the prediction of adequate serum levels
based on doses calculated according to mg/kg/day and m2/day. This is an observational
reprospective cohort at a referral neonatal unit, from 2011 to 2013. Newborns treated with
vancomycin for the ﬁrst episode of late-onset sepsis were included. Total dose in mg/kg/day,
dose/m2/day, age, weight, body surface and gestational age were identiﬁed as independent
variables. For predictive analysis of adequate serum levels, multiple linear regressions were
performed. The Receiver Operating Characteristic curve for proper serum vancomycin levels
was also obtained. A total of 98 patients received 169 serum dosages of the drug, 41 (24.3%) of
the  doses had serum levels that were deﬁned as appropriate. Doses prescribed in mg/kg/day
and dose/m2/day predicted serum levels in only 9% and 4% of cases, respectively. Statistical
signiﬁcance was observed with higher doses when the serum levels were considered as
appropriate (p < 0.001). A dose of 27 mg/kg/day had a sensitivity of 82.9% to achieve correct
serum levels of vancomycin. Although vancomycin has erratic serum levels and empirical
doses  cannot properly predict the target levels, highest doses in mg/kg/day were associatedwith  adequate serum leve
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Introduction
The introduction of new technologies in neonatal units has
caused high nosocomial infection rates with subsequent
complications among newborns. Coagulase-negative Staphy-
lococcus has been identiﬁed as the main nosocomial agent,
affecting more  than 50% of all cases of late-onset neonatal
sepsis.1–3
Vancomycin is widely used for conﬁrmed or suspected
neonatal sepsis as around 90% of coagulase negative Staphylo-
cocci strains are oxacillin and penicillin-resistant.4,5 However,
toxicity, pharmacokinetic variability and empirical doses used
for newborns are important topics related to vancomycin use
in this population.6–11 Measurement of area under the curve
to achieve minimum inhibitory concentration (MIC) against
Staphylococci is an important parameter to therapeutics with
this drug.6,7
The usual empirical dose for the neonatal population
ranges from 10 to 15 mg/kg/dose, administered one to four
doses a day.1,3,5,8 However, studies in pediatric population
have reported on the need for higher doses of vancomycin, up
to 60 mg/kg/day, in order to achieve the desired serum level.6,7
A minimum recommended through serum level of at least
5–10 mcg/mL is required for effective therapy and fewer side
effects, including nephrotoxicity.8–10 Higher concentration tar-
gets ranging from 15 to 20 mcg/mL are recommended even
for children with more  severe infections such as osteomyelitis
and meningitis.6,11
However, empirical dose of vancomycin is not ideal accord-
ing to inappropriate serum levels of the drug that have been
reported in neonates in several studies.5,9,10,12,13 Although
there have been previous descriptions of dose calculations
based on nomograms  and adjustments according to drug
clearance and the patient’s renal function,5,14–17 no study has
analyzed doses that were prescribed according to body sur-
face (m2/day) and the resulting serum vancomycin levels.
We hypothesized that higher serum levels could be achieved
based on doses calculated according to body surface.
The present study was conducted in order to evaluate
serum levels of vancomycin that were used to treat late-
onset sepsis in newborns and compare the prediction of
adequate serum levels based on doses calculated according
to mg/kg/day and m2/day.
Material  and  methods
Design
This is an observational retrospective cohort, real life study,
held at the Neonatal Progressive Care Unit (NPCU) of the Hos-
pital das Clinicas, Federal University of Minas Gerais, from
January 2011 to June 2013.
Inclusion  criteriaNewborns who  were admitted to the NPCU, diagnosed with
Healthcare Associated Infections (HAI), and treated with van-
comycin for the ﬁrst episode of late-onset sepsis (deﬁned as 1 6;2  0(5):451–456
sepsis after 48 h of age), were included in this study if they had
vancomycin level tested as recommended.
Data  collection
Information was collected through prospective and active
surveillance of infants at risk by trained professionals of the
Hospital Infection Control Commission (HICC). Standardized
information about gestational age at delivery, birth weight,
gender, data and criteria for diagnosis and treatment of blood-
stream infection are routinely registered.
Clinical or laboratory-conﬁrmed bloodstream infection fol-
lowed the criteria of the Agência Nacional de Vigilância
(ANVISA) based on National Healthcare Safety Network of the
Centers for Diseases Control and Prevention recommenda-
tions.
a) Clinical Bloodstream Infection – at least one of clinical
signs (thermal instability, apnea, bradycardia, food intoler-
ance, worsening respiratory distress, glucose intolerance,
hemodynamic instability, and hypoactivity or lethargy)
AND all of following criteria: hemogram with three altered
parameters or increased C-Reactive protein; not performed
or negative blood culture; no evidence of infection at
another site; antimicrobial therapy initiated or sustained
by the attending physician.
b) Laboratory-conﬁrmed bloodstream infection – at least one
of clinical signs (thermal instability, apnea, bradycardia,
food intolerance, worsening respiratory distress, glucose
intolerance, hemodynamic instability and hypoactivity or
lethargy) not related to an infection at another site AND at
least one of the following:
- common skin contaminant cultured from two  or more
blood cultures drawn on separate occasions;
- common skin contaminant (e.g., diphtheroids, Bacillus
sp., Propionibacterium sp., coagulase-negative staphylo-
cocci, or micrococci) cultured from at least one blood
culture from a patient with an intravascular line, and the
physician institutes appropriate antimicrobial therapy.
Information were collected daily and systematically
included in the HICC internal program for further analysis.
Main  outcome
Vancomycin levels were always collected before next dose,
corresponding to through levels. Adequate serum levels
of vancomycin were considered as those between 10 and
20 mg/dL. According to recent studies and considering that
neonatal sepsis is a severe event, levels below 10 mg/dL were
considered as decreased and inappropriate while those above
20 mg/dL were deﬁned as increased and inappropriate.6,9,10
Statistical  analysis
Statistical analysis was performed with the Statistical Package
for Social Sciences (SPSS Inc., USA), version 19.0.
Total dose in mg/kg/day, dose/m2/day, age, weight, body
surface and gestational age at delivery were independent vari-
ables in the predictive model of adequate serum levels in
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Table 1 – Simple linear regression for prediction of
adequate serum vancomycin levels, referral Neonatal
Unit for Progressive Care, Hospital das Clínicas/UFMG,
Belo Horizonte, Brazil, from 2011 to 2013.
Predictive variable R2 F p
Dose in mg/kg/day 0.092 16.85 <0.001
Dose in m2/day 0.036 6.21 0.014
Weight (grams) 0.051 8.99 0.003
Gestational age (weeks) 0.039 6.78 0.01
Body surface (m2) 0.360 6.21 0.004
Postnatal age 0.002 0.41 0.525
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Fig. 1 – Scatter plot diagram of prediction correlation for
adequate serum levels of vancomycin considering the total
dose in mg/kg/day, referral Neonatal Unit for Progressive
Care, Hospital das Clínicas/UFMG, Belo Horizonte, Brazil,
from 2011 to 2013.
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Fig. 2 – Scatter plot diagram of prediction correlation for
adequate serum levels of vancomycin considering the totalb r a z j i n f e c t d i s .
imple linear regression. Statistical signiﬁcance was consid-
red when p < 0.05. Multiple linear regression was performed
ith all variables with p < 0.05 in univariate linear regression.
Total daily doses of vancomycin was considered as
roposed by previous published studies6,7,10,11,13,17 because
eonatal doses can vary according to birth weight and post-
estational age.
Doses were compared among groups according to appropri-
te (group 1) and inappropriate (group 2) serum levels, using
he Mann–Whitney (when variables presented non-normal
istribution) or t-test (when variables presented normal dis-
ribution).
The Receiver Operating Characteristic curve (ROC curve) for
roper serum vancomycin levels was also obtained.
thics  considerations
he study was approved by the Institutional Ethics Committee.
esults
 total of 98 patients were included in analysis and the mean
estational age was 33.52 weeks (SD = 4.41) and 63 patients
64.3%) were premature. Forty-eight (49%) were male and the
verage age at the start of vancomycin treatment was 18.4 days
SD = 16.5).
First measurement of vancomycin levels of 95 patients
howed that 28 (28.6%) of them adequate values, 57 (58.2%) had
iminished levels (below 10 mg/dL) and 10 (10.2%) presented
igher levels (above 20 mg/dL). Three patients had their ﬁrst
ancomycin dose modiﬁed without serum levels of the drug.
During treatment, there were a total of 169 serum measure-
ents of the drug, with an average of 1.72 doses per patient.
here were 64 dose modiﬁcations based on the serum levels.
hus, the average number of modiﬁcations per patient was
.72 (SD = 0.89) with a median of 1, and varying from 1 to 5
imes.
Among the 169 measurements, 41 (24.3%), 112 (66.3%), and
6 (9.5%) had serum levels that were deﬁned as adequate,
iminished, and above the target value, respectively.
The simple linear regression model showed that doses pre-
cribed in mg/kg/day predicted serum levels in only 9% of
ases, but higher doses presented a signiﬁcant association
ith high serum vancomycin levels (p < 0.001). Doses that were
rescribed in dose/m2/day showed similar results, with ade-
uate serum prediction in only 4% of cases. However, a higher
tatistical association was observed between higher doses
nd higher serum vancomycin levels (p = 0.014). Weight, ges-
ational age, and body surface did not predict adequately the
erum levels in multiple regression analysis (Table 1).
The diagram of dose dispersion in mg/kg/day (Fig. 1) and
ose in m2/day (Fig. 2) revealed that although there was no
roper prediction with any of the doses for the calculation
asis, doses that were calculated in m2/day showed higher
omogeneity in graphical distribution.
During multiple linear regression analysis for the predic-
ion of the serum levels, only the prescribed dose in mg/kg/day
resented with statistically signiﬁcant associations (p < 0.001).
dose/m2/day, referral Neonatal Unit for Progressive Care,
Hospital das Clínicas/UFMG, Belo Horizonte, Brazil, from
2011 to 2013.
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Fig. 3 – Receiver Operating Characteristic curve (ROC curve)
to dose in mg/kg/day and adequate serum vancomycin,
referral Neonatal Unit for Progressive Care, Hospital das
Clínicas/UFMG, Belo Horizonte, Brazil, from 2011 to 2013.
Statistical differences were observed when dose in
mg/kg day was compared among groups (Mann–Whitney
with p < 0.001) (Group 1 median = 36; Group 2
median = 27 mg/kg/day). However, differences between groups
were not observed when compared to dose/m2/day (p = 0.213)
(Group 1 median = 195.6; Group 2 median = 194 mg/m2/day).
After excluding 16 patients with increased serum lev-
els (outliers), we  compared patients with low and adequate
serum levels. Mann–Whitney also showed statistically signif-
icant differences when compared to total dose in mg/kg/day
among groups with adequate and decreased (p < 0.001) (Group
1 median = 36; Group 2 median = 20 mg/kg/day).
Statistically signiﬁcant differences between the serum
level values in term (mean 10.91 mg/dL, SD 6.88) and preterm
infants (average 8.05 mg/dL; DP7, 46) were observed. Higher
serum levels were achieved in the ﬁrst group (t-test = 2.52;
p = 0.013).
When comparing the value of the serum level achieved
according to days of life, there were no observed differences
in serum levels between newborns at ≤7 days (median 9.14,
SD = 7.22) or >7 days of life (mean 9.16, SD = 7.33; t-test = 0.12
and p = 0.99.1).
In Fig. 3, the ROC curve for dose in mg/kg/day correlated to
adequate serum levels. An AUC of 0.706 was considered as the
minimum for a satisfactory (95% CI 0.617–0.795) result. A dose
of 27 mg/kg/day had a sensitivity of 82.9% to achieve correct
serum levels of vancomycin.
Discussion
Vancomycin doses in mg/kg/day were not highly predictive
of adequate serum levels but higher doses were signiﬁcantly
associated with adequate vancomycin serum levels. Other ret-
rospective studies in the neonatal and pediatric population
also showed poor performance of empirical treatments with
vancomycin, with adequate target levels of 25–34%, consider-
ing trough levels from 10 to 20 mg/L.9,10,18 Even in studies that 1 6;2  0(5):451–456
considered baseline serum levels from 5 to 15 mg/L, suitable
dosages ranged from 31 to 66%.4,12,13,18
In this study, a dose of 27 mg/kg/day could be the minimum
recommended dose for newborns. Although empirical recom-
mended doses vary from 10 to 15 mg/kg, intervals between
doses often vary from q48 to q6 h, achieving a low percentage
of vancomycin target levels.4,10,12,18,19
The main reasons for monitoring the dose of vancomycin
by serum concentrations are for maintaining therapeutic lev-
els and preventing ototoxicity and nephrotoxicity.8,20
Considering that vancomycin has an erratic distribution
and renal elimination, the duration of action is crucial for
achieving and maintaining serum levels which indicated the
need for longer dosing intervals. Hoog et al.13 compared the
use of 30 mg/kg/day at 12-h and 8-h intervals, and a percentage
of the appropriate concentration of 95% was achieved when
shorter intervals were used. In the model described by Dersch-
Mills et al.10 dose adjustments of 10 mg/kg every 6 hours were
necessary in order to reach adequate serum levels in 72% of
cases.
Even clinical trials of continuous dose infusion indicated
the need of 30 mg/kg/day to achieve 75–90% of suitable serum
levels.17,21 Zhao et al.15 preformed a prospective study with
continuous infusion of vancomycin with doses simulation
ranging from 15 to 35 mg/kg/day and the authors reported
70.7% of serum levels between 15 and 25 mg/L.
In the present study, even higher doses were observed in
the group that reached the appropriate level with a median of
36 mg/kg/day and a median of one dose modiﬁcation.
In a retrospective study among pediatric patients with
normal renal functions, Glover et al.22 observed the need to
modify doses at least once on average (ranging from 1 to
4 times) in order to achieve adequate serum levels, which
required up to 60 mg/kg/day of vancomycin.
Doses that were administered in m2/day were not inves-
tigated in a previous study. Although predicting the serum
level was even lower than that achieved by mg/kg/day, the
scatter plot diagram revealed a greater homogeneity of mea-
surements. Possibly larger doses are needed in mg/m2 in
order to achieve adequate serum levels. The high percent-
ages of body water and extracellular space in newborns lead
to lower plasma drugs concentrations that diffuse into these
compartments.23,24 Thus, in children aged less than two years,
hydrophilic drugs with low volume of distribution should be
normalized by body surface,25 and similarly considered for
vancomycin.
It is noteworthy that full-term babies had higher serum
median levels (10.91 mg/dL) compared to preterm newborns
but the difference was not signiﬁcant when adjusting for
days of postnatal life. It is known that vancomycin phar-
macokinetics is affected by the immaturity of the renal
function of preterm infants and drug half-life and clearance
are even higher in preterm newborns due to the high per-
centage of body water, especially during the ﬁrst postnatal
week.26,27
Some authors suggest dose adjustment through nomo-
grams and formulae.28 Studies investigating these methods
in the neonatal population should consider the maturation of
renal function and vancomycin clearance for dose calculation
and adjustment for drug maintenance.4,14–17,29
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Doses of up to 60 mg/kg/day of vancomycin are recom-
ended for children under one year of age based on a study
hat reached AUC/MIC >400, which is considered appropriate
or the treatment of Staphylococcus aureus.7 Stockmann et al.30
ave also considered target concentrations of AUC/MIC >400 in
eonates and observed the linear correlation between greater
UC and higher serum levels.
Despite being a study with prospective and active surveil-
ance, there were difﬁculties related to information collection
ue to non-standardized procedures related to antibiotics pre-
cription by the clinical staff. Vancomycin serum levels were
ot always performed as demanded and dose modiﬁcations
ere observed even without monitoring, limiting the number
f drug evaluations.
In conclusion, vancomycin has erratic serum levels and
mpirical doses calculated in mg/kg/day or m2/day cannot
roperly predict the target levels. Doses based in m2/day
howed higher homogeneity. Besides, higher doses based in
g/kg/day were associated with adequate serum levels, even
fter adjusting for gestational age, weight, and body surface.
onsidering the inﬂuence of these variables on drug distri-
ution, this indicates necessity for higher doses, as at least
0 mg/kg/day, in order to achieve the target and therapeutic
evels.
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